Migration of human neural stem cells toward an intracranial glioma.
- Author:
Jeong Yong JEON
1
;
Jeung Hee AN
;
Seung Up KIM
;
Hye Gyeong PARK
;
Myung Ae LEE
Author Information
- Publication Type:Original Article ; Research Support, Non-U.S. Gov't
- Keywords: glioma; stem cells; tissue therapy; tropism
- MeSH: Animals; Brain/*cytology/*pathology; Brain Neoplasms/*pathology; *Cell Movement; Female; Glioma/*pathology; Humans; Mice; NIH 3T3 Cells; Neurons/*cytology; Rats; Rats, Sprague-Dawley; Stem Cells/*cytology
- From:Experimental & Molecular Medicine 2008;40(1):84-91
- CountryRepublic of Korea
- Language:English
- Abstract: Many in vivo and in vitro studies have demonstrated the targeted migration of neural stem cells (NSC) to infiltrating brain tumors, including malignant glioma, highlighting a potential therapeutic approach. However, there is not enough information to apply this approach to clinical therapy. The most important things in stem cell therapy for brain tumors involve selecting the appropriate neural progenitor type and optimizing the efficiency of the cell engraftment. By histological analysis using two different live-dyes, human NSCs were shown to migrate away from the transplanted site in the direction of the expanding C6 glioma and to intermix with the tumor bed, especially with the tumor core. This intermixing occurred within 7 days when NSCs were implanted into glioma model. The time course of migratory HB1.F5 with the greatest mobility of three NSC lines was as follows. As early as 3 days after transplantation, several NSCs were found leaving the implant site, primarily approaching microsatellites and frontier cells located near the site of NSC implantation. Through 7 days post-transplantation, massive numbers of NSCs continued to be attracted to and interspersed with C6 glioma, and were finally distributed extensively throughout the whole tumor bed, including the core and penumbra of the tumor mass. However, NSCs appeared to penetrate into the tumor mass very well, whereas normal fibroblast cells could not migrate. These findings strengthen the potential for human NSCs as attractive vehicles to improve therapeutic gene delivery to cancer or glioma if they are optimized to selectively kill neoplastic cells.
